Cellid Co. Ltd (299660) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Cellid Co. Ltd stock KRW 1,528, price KRW 1,700, that is 10.1% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Cellid Co. Ltd
299660 · KQExpensive (fair value 10% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 1,025 KRW – 127,128 KRW · fair‑value band 1,146 KRW – 1,910 KRW · the 1,700 KRW price screens above the 1,528 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Cellid Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies.
Show moreShow less
It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens.
The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
Stock analysis
Cellid Co. Ltd (299660) currently trades at 1,700 KRW, while our estimate is 1,528 KRW, 10% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 1,146 KRW (bear) to 1,910 KRW (bull), the price of 1,700 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Cellid Co. Ltd reported revenue of 8.8B KRW in FY2025 versus 909M KRW in FY2021, a compound +76.6%/yr. Reported net income was −12.1B KRW in FY2025.
Key figures
Market cap 52.9B KRW (≈ $39.8M) Micro · P/S ratio 13.9 · Net margin −137% · Return on equity −26.7% · Return on assets (EBIT) −19.8% (5-year average) · Operating margin −768% · Revenue (TTM) 4.2B KRW · Free cash flow −35.6B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 59% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, 299660 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Cellid Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/B ratio by industry
- Net margin by industry
- Stock screener with 62 metrics
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs 299660 |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs 299660 |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs 299660 |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs 299660 |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs 299660 |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs 299660 |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs 299660 |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs 299660 |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs 299660 |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs 299660 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Cellid Co. Ltd (299660) overvalued or undervalued?
What is the fair value of 299660?
What is the quality score of 299660?
What is the price target for Cellid Co. Ltd (299660)?
What is the Cellid Co. Ltd stock forecast for 2026?
What is the revenue of Cellid Co. Ltd (299660)?
What is the intrinsic value of Cellid Co. Ltd (299660)?
Is Cellid Co. Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 299660?
How much is Cellid Co. Ltd worth?
What do the bullish and bearish scenarios say about 299660?
How solid is the balance sheet of Cellid Co. Ltd (299660)?
How far is 299660 from its 52-week high?
Which stocks are comparable to Cellid Co. Ltd?
Is Cellid Co. Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Cellid Co. Ltd (299660)?
What should I pay attention to with Cellid Co. Ltd right now?
Key figures of Cellid Co. Ltd
How large is the market capitalisation of Cellid Co. Ltd (299660)?
What is the P/S ratio of Cellid Co. Ltd (299660)?
What is the net margin of Cellid Co. Ltd (299660)?
What is the return on equity of Cellid Co. Ltd (299660)?
What is the EBIT return on assets of Cellid Co. Ltd (299660)?
What is the operating margin of Cellid Co. Ltd (299660)?
How much free cash flow does Cellid Co. Ltd (299660) generate?
How much net debt does Cellid Co. Ltd (299660) carry?
Watch Cellid Co. Ltd in the live analysis
One click puts Cellid Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.